The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.
 
Tanya Siddiqi
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Kite, a Gilead company
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene
Research Funding - Acerta Pharma (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
David G. Maloney
Stock and Other Ownership Interests - A2 Biotherapeutics; Navan Technologies
Honoraria - Bristol-Myers Squibb; Caribou Biosciences; Celgene; Genentech; Incyte; Juno Therapeutics; Kite, a Gilead Company; Lilly O.; MustangBio; Novartis; Umoja Biopharma
Consulting or Advisory Role - A2 Biotherapeutics; Bristol-Myers Squibb; Chimeric Therapeutics; Genentech; Gilead Sciences; ImmPACT Bio; Interius Biotherapeutics; Navan Technologies
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead Company (Inst); Legend Biotech (Inst)
Patents, Royalties, Other Intellectual Property - ights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMS
 
Saad Kenderian
Stock and Other Ownership Interests - LEAH Labs; Lifengine Technologies
Consulting or Advisory Role - Calibr; Capstan Therapeutics; Humanigen; Kite, a Gilead Company; Novartis
Research Funding - Humanigen (Inst); Juno/Bristol-Myers Sqibb (Inst); Kite/Gilead (Inst); LEAH Labs (Inst); Lentigen (Inst); Morphosys (Inst); Novartis (Inst); Sunesis Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Humanigen; Humanigen (Inst); Mettaforge Therapeutics; Mettaforge Therapeutics (Inst); MustangBio; MustangBio (Inst); Novartis; Novartis (Inst)
 
Danielle M. Brander
Honoraria - Abbvie/Genentech; Pharmacyclics
Consulting or Advisory Role - Genentech/Abbvie; Pharmacyclics
Research Funding - Abbvie (Inst); ArQule (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Catapult Therapeutics (Inst); DTRM (Inst); Genentech (Inst); MEI Pharma (Inst); Newave Pharmaceutical (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Kathleen Anne Dorritie
Honoraria - DAVA Pharmaceuticals; Onc Live
Research Funding - Genentech/Roche; Genmab/Seattle Genetics; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company
 
Jacob Soumerai
Consulting or Advisory Role - Abbvie; AstraZeneca; Beigene; Bristol-Myers Squibb; Roche; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies (Inst); Beigene (Inst); BostonGene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Moderna Therapeutics (Inst); TG Therapeutics (Inst)
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; ADC Therapeutics; BeiGene; Bristol-Myers Squibb; CVS Caremark; Genmab; Intellia Therapeutics; Janssen; Kite/Gilead; Nektar; Novartis; Nurix; Sana Biotechnology; Takeda
Speakers' Bureau - Kite/Gilead
Research Funding - Bristol-Myers Squibb (Inst); Calibr (Inst); Fate Therapeutics (Inst); Kite/Gilead (Inst); MorphoSys (Inst); Novartis (Inst); Tessa Therapeutics (Inst); Xencor (Inst)
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Rajneesh Nath
Consulting or Advisory Role - Incyte
 
Bita Fakhri
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; Beigene; Bristol-Myers Squibb; CSL Behring; Loxo@Lilly; pharmacyclics
Research Funding - Abbvie (Inst); Angiocrine Bioscience (Inst); Bristol-Myers Squibb (Inst); Loxo@Lilly (Inst)
Travel, Accommodations, Expenses - Abbvie
 
Deborah Marie Stephens
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BMS; Celgene; CSL Behring; Genentech; Lilly; TG Therapeutics
Research Funding - Acerta Pharma; ArQule; Iovance Biotherapeutics; Juno Therapeutics; Karyopharm Therapeutics; MingSight; Newave Pharmaceutical; Newave Pharmaceutical (Inst); Novartis
 
Shuo Ma
Honoraria - Abbvie; AstraZeneca; Beigene; Bristol-Myers Squibb; Clinical Care Options; Curio Science; Dava Oncology; Genentech; Janssen; Lilly O.; Medscape; OncLive; TG Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Beigene; Bristol-Myers Squibb; Genentech; Janssen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Beigene; Janssen; Lilly O.; Pharmacyclics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Beigene (Inst); Juno Therapeutics (Inst); Loxo (Inst); TG Therapeutics (Inst)
 
Tatyana A Feldman
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen; Takeda
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genmab; Seagen
Speakers' Bureau - Kite, a Gilead company; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Cell Medica (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Pfizer (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst); Viracta Therapeutics (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Seagen; Takeda
 
Scott R. Solomon
No Relationships to Disclose
 
Stephen J. Schuster
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; BeiGene; Celgene; Genentech/Roche; Incyte; Janssen; Legend Biotech; Loxo; MorphoSys; MustangBio; Nordic Nanovector; Novartis; Regeneron
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors via University of Pennsylvania with royalties to Novartis
 
Serena K. Perna
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb (I)
 
San-San Ou
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb (I)
 
Eniko Papp
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb (I)
 
Yizhe Chen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb (I)
Patents, Royalties, Other Intellectual Property - University of Kentucky (I)
 
William G. Wierda
Research Funding - AbbVie (Inst); Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Loxo (Inst); Novartis (Inst); Oncternal Therapeutics (Inst)
Travel, Accommodations, Expenses - AbbVie; Genentech; Lilly O.